ResMed RMD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 234.2%+11.4pp | 222.8%-2.8pp | 225.6%-0.8pp | 226.4%-5.8pp | |
| Operating margin | 126%+19.9pp | 106.1%-4.1pp | 110.3%-2.2pp | 112.5%-1.1pp | |
| Net margin | 101.9%+18.7pp | 83.2%-2.8pp | 85.9%+12.1pp | 73.9%-0.8pp | |
| EBITDA margin | 140.7%+18.9pp | 121.8%-4.6pp | 126.5%-4.2pp | 130.7%-3.2pp | |
| Free cash flow margin | 119.9%+28.4pp | 91.5%+52.2pp | 39.3%-2.8pp | 42.1%-50.5pp | |
| Returns | |||||
| Return on equity | 100.9%+10.5pp | 90.3%-5.4pp | 95.8%+9.9pp | 85.9%-5.8pp | |
| Return on assets | 70.6%+13.1pp | 57.5%-2.6pp | 60.1%+5.9pp | 54.2%+2.8pp | |
| Return on invested capital | 92.7%+19.6pp | 73.1%-4.9pp | 78%+5.4pp | 72.6%+1.6pp | |
| Efficiency | |||||
| Asset turnover | 2.8×0.0× | 2.8×0.0× | 2.8×-0.1× | 2.9×+0.2× | |
| Inventory turnover | 9.3×+0.6× | 8.7×+0.1× | 8.6×-2.4× | 11×-1.2× | |
| Liquidity | |||||
| Current ratio | 13.1×+1.4× | 11.7×-0.6× | 12.3×+1.9× | 10.4×+1.9× | |
| Quick ratio | 9.2×+1.9× | 7.3×+0.2× | 7.1×+0.5× | 6.5×+0.7× | |
| Cash ratio | 3.3×+2.1× | 1.1×-0.1× | 1.2×-0.2× | 1.5×-0.3× | |
| Leverage | |||||
| Debt-to-equity | 0.6×-0.5× | 1.1×-0.5× | 1.6×+0.5× | 1.1×-0.3× | |
| Debt-to-assets | 0.5×-0.3× | 0.7×-0.2× | 1×+0.2× | 0.7×-0.1× | |
| Net debt / EBITDA | 0.2×-2.8× | 3×-1.3× | 4.3×+2.0× | 2.3×-0.2× | |
| Per Share | |||||
| Book value per share | $148.99+20.6% | $123.56+19.5% | $103.38+18.6% | $87.17+14.4% | |
| Valuation | |||||
| Market capitalization | $139.84B+34.1% | $104.29B-17.7% | $126.78B-11.0% | $142.49B+18.6% | |
| Enterprise value | $140.17B+29.3% | $108.36B-18.0% | $132.08B-9.0% | $145.13B+18.2% | |
| Price / earnings | 110.9×+0.6× | 110.3×-41.1× | 151.4×-83.0× | 234.4×+15.8× | |
| Price / sales | 28.1×+5.2× | 22.9×-9.6× | 32.5×-8.5× | 41.1×+2.4× | |
| Price / book | 25.5×+2.7× | 22.8×-10.6× | 33.4×-11.3× | 44.7×+1.7× | |
| EV / EBITDA | 80.3×+2.0× | 78.3×-28.9× | 107.2×-20.8× | 128×+9.9× | |
| EV / sales | 28.2×+4.3× | 23.8×-10.1× | 33.9×-7.9× | 41.8×+2.3× | |
| Free cash flow yield | 17.1%+1.2pp | 15.9%+11.0pp | 4.9%+0.9pp | 4%-5.7pp | |
| Earnings yield | 14.6%-0.1pp | 14.6%+4.0pp | 10.6%+3.2pp | 7.4%-0.5pp | |
| Dividend yield | 3.4%-0.8pp | 4.2%+1.0pp | 3.2%+0.5pp | 2.7%-0.4pp | |
| PEG ratio | 3.5×-5.7× | 9.2×+1.9× | 7.2×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ResMed's profit margins?
- ResMed (RMD) runs a 61.6% gross margin and a 34.2% operating margin, with a 27.4% net margin.
- Where do ResMed's ratios come from?
- Every ratio is computed from ResMed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
